Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Analyst/ Institutional Investor Meeting09-11-2023
09-11-2023
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Earning call transcript for Q2 H1 FY2408-11-2023
Dr. Lal Pathlabs Share Price Live blog for 06 Nov 2023
Dr. Lal Pathlabs stock price went up today, 06 Nov 2023, by 5.2 %. The stock closed at 2465.2 per share. The stock is currently trading at 2593.4 per share. Investors should monitor Dr. Lal Pathlabs stock price closely in the coming days and weeks to see how it reacts to the news.06-11-2023
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication - Q2 & H1 Financial Results for the period ended September 30, 202303-11-2023
Brokerages maintain cautious stance on Dr. Lal PathLabs post Q2 recovery
The diagnostics player reported a 52.4 percent year-on-year rise in consolidated net profit at Rs 109.3 crore for the July-September quarter of the current financial year03-11-2023
Dr. Lal Pathlabs Share Price Live blog for 03 Nov 2023
Dr. Lal Pathlabs stock price went up today, 03 Nov 2023, by 3.3 %. The stock closed at 2377 per share. The stock is currently trading at 2455.55 per share. Investors should monitor Dr. Lal Pathlabs stock price closely in the coming days and weeks to see how it reacts to the news.03-11-2023
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the audio recording of the Company's Conference Call dated November 02, 2023 with Investors/ Analysts for Q2 & H1 FY24 is available on the Company's website02-11-2023
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meeting02-11-2023
Q2FY24 Quarterly Result Announced for Dr. Lal Pathlabs Ltd.
Healthcare Services company Dr. Lal Pathlabs announced Q2FY24 results: 1. Financial Performance - Total revenue of Rs 601 crore in Q2FY24, an increase of 12.6% compared to Q2FY23. - Revenue excluding RTPCR increased by 14.4% in Q2FY24. - EBITDA margin for Q2FY24 was 29.6%. - PBT for Q2FY24 was Rs 152 crore. - PAT for Q2FY24 was Rs 111 crore. - PAT margin for Q2FY24 was 18.4%. - The company's EPS for Q2FY24 was 13.2. 2. Operating Expenditure - Operating Expenditure for Q2FY24 was Rs 424 crore. - Operating Expenditure increased by 8.6% compared to Q2FY23. 3. Other Financial Highlights - Other Income for Q2FY24 was Rs 18 crore. - Depreciation cost for Q2FY24 was Rs 36 crore. - Finance cost for Q2FY24 was Rs 8 crore. Result PDF02-11-2023
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on the Financial Results for the Q2 & H1 FY 2402-11-2023